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tially outside the recommenda-
tions of the EMA, the G-BA, and 
clinical guidelines. Such audits 
are very rare in practice. Limits 
on insurer interference reflect the 
recognition by health insurance 
plans that moderation in drug 
spending is to be pursued by 
means of control over prices 
rather than control over physi-
cian prescribing and patient ad-
herence. Some observers have rec-
ommended that the United States 
adopt an analogous model, un-
der which manufacturers agree 
to accept value-based prices in 
exchange for insurers reducing 
prior-authorization requirements 
and cost sharing so as not to im-
pede appropriate patient access.5
The German system for deter-
mining drug prices features col-
lective negotiations on the part 
of competing health plans rather 
than price regulation by a single 
government agency. A statutory 
framework that creates incentives 
for agreement, limits price in-
creases not justified by new evi-
dence, and avoids heavy burdens 
on physicians and patients ensures 
that public interests are repre-
sented in private negotiations. 
Perhaps most important over the 
long run, the German structure 
has gained legitimacy among its 
principal stakeholder groups, in-
cluding physicians, patient advo-
cates, drug manufacturers, health 
plans, and the broader public. It 
remains to be seen whether the 
contemporary policy debate and 
political turmoil in the United 
States will also generate an eco-
nomically efficient and socially 
accepted drug-pricing system.
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According to a report by the Congressional Budget Office, 
roughly 1% of prescription drugs 
dispensed under Medicare Part D 
and Medicaid accounted for about 
30% of net drug spending in 
each program in 2015.1 The 
agency found that between 2010 
and 2015, net spending on these 
so-called specialty drugs rose 
from $8.7 billion to $32.8 billion 
in Medicare Part D and from 
$4.8 billion to $9.9 billion in 
Medicaid. Similarly, spending on 
specialty drugs by commercial 
plans nearly quadrupled between 
2003 and 2014.2
The origins of the specialty-
drug label can be traced back to 
the 1970s, when specialty phar-
macies emerged in response to 
the need for preparation and de-
livery of new injectable and infu-
sion products. Only a handful of 
drugs required such handling at 
the time and were called “spe-
cialty drugs.” Today, various stake-
holders in the pharmaceutical 
supply chain assign the specialty 
label to drugs on the basis of a 
combination of several unrelated 
factors, such as whether a drug 
treats a rare condition, requires 
special handling, or needs post-
marketing risk-management plans.
But the single most common 
feature of specialty drugs is high 
cost. Indeed, the Centers for 
Medicare and Medicaid Services 
(CMS) defines specialty drugs as 
those with monthly costs exceed-
ing $670. The specialty-drug la-
bel has important consequences 
for patients. When Medicare Part D 
went into effect in 2006, CMS ex-
plicitly permitted plans to place 
specialty drugs on the highest 
cost-sharing tiers of their formu-
laries. Today, virtually all Part D 
plans have a specialty tier. The 
maximum allowable coinsurance 
for drugs on such tiers is 33%. A 
new proposed rule from CMS 
would allow Part D plans to im-
plement a “preferred” specialty tier 
with a lower cost-sharing rate.
The economic burden of these 
cost-sharing requirements on pa-
tients can be substantial. Part D 
enrollees not receiving low-income 
subsidies can pay thousands of 
dollars out of pocket per year for 
a single specialty-tier drug.3 Nu-
merous disease-modifying ther-
apies used for treating multiple 
sclerosis are considered specialty 
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drugs, for example, and by one es-
timate, patients in standard Part D 
plans taking one of these drugs 
had average projected out-of-pocket 
spending of $6,894 in 2019.4
Labeling all expensive drugs as 
specialty drugs and placing them 
on the highest cost-sharing tiers 
in plan formularies is an ap-
proach taken only by the U.S. 
health care system. By our esti-
mate, in 2018, more than four 
fifths of new outpatient drugs 
that were covered by Medicare 
Part D during the year after they 
were approved by the Food and 
Drug Administration (FDA) were 
assigned to specialty tiers. Prior-
authorization requirements are 
often implemented for drugs on 
specialty tiers. The specialty-drug 
label has become a blunt instru-
ment for imposing financial obli-
gations and administrative barri-
ers on patients in response to the 
very high prices set for new drugs 
by manufacturers.
Other high-income countries 
undertake value-based assessments 
to determine whether a drug’s 
cost is justified, given its bene-
fits. In the United Kingdom, for 
example, the National Institute 
for Health and Care Excellence 
(NICE) evaluates the cost-effec-
tiveness of a drug and makes a 
recommendation regarding cover-
age of that drug to the National 
Health Service (NHS). The same 
cost-effectiveness threshold applies 
to essentially all drugs (with the 
exception of drugs for end-of-life 
care and very rare conditions, for 
which a higher threshold is used). 
An expensive drug can still repre-
sent a cost-effective use of health 
care resources if it costs less 
than £30,000 (about $36,500) per 
quality-adjusted life-year (QALY) 
gained. If a drug is found not to 
be cost-effective, the government 
seeks to negotiate an additional 
(confidential) discount with the 
manufacturer to push the price 
under the accepted threshold. 
Once a drug receives a positive 
recommendation from NICE, the 
NHS makes it available without 
cost sharing for most patients 
(nearly 90% of prescriptions were 
dispensed free of charge in 2016). 
If a drug receives a negative rec-
ommendation, it is not available 
for patients in the NHS. Cover-
age has been denied for less than 
20% of drugs appraised in NICE’s 
two-decade history.
Similarly, the Canadian Agen-
cy for Drugs and Technologies in 
Health assesses the comparative 
clinical- and cost-effectiveness of 
new drugs. This Common Drug 
Review process informs reim-
bursement decisions for Canada’s 
federal, provincial, and territorial 
public drug plans, except in Que-
bec. Although the agency doesn’t 
have a formal cost-effectiveness 
threshold, drugs that receive a 
positive recommendation for re-
imbursement generally cost less 
than $50,000 Canadian (about 
$35,500) per QALY gained.
In the United States, however, 
expensive drugs that offer added 
therapeutic benefit over existing 
alternatives are typically placed 
on specialty tiers alongside other 
expensive drugs that don’t offer 
such benefit. For example, soni-
degib (Odomzo) was initially ap-
proved by the FDA in 2015 for 
treating basal-cell carcinoma. Ac-
cording to a comparative clinical-
effectiveness assessment conduct-
ed by the Haute Autorité de Santé, 
France’s national health author-
ity, sonidegib doesn’t offer mean-
ingful added therapeutic benefit 
over existing alternatives. Idelalisib 
(Zydelig) was approved in 2014 
as a first-in-class treatment for 
certain blood cancers. It has been 
widely deemed to offer added 
therapeutic benefit over other 
treatments. Despite these differ-
ences, both drugs are currently 
placed on the specialty tiers of 
more than 90% of Part D plans, 
meaning that patients prescribed 
these drugs could be responsible 
for equivalent coinsurance rates.
We believe that the United 
States should abandon the now-
meaningless specialty-drug label 
for high-cost drugs and instead 
categorize therapies according to 
their comparative clinical- and 
cost-effectiveness, as is routinely 
done in other high-income coun-
tries, such as Canada and England. 
Health plans could then use value-
based categories to inform cover-
age and tier-placement decisions 
in their formularies. Comparative 
clinical- and cost-effectiveness 
analyses could be used to deter-
mine value-based price bench-
marks, which would then guide 
decisions regarding coverage of 
drugs in plan formularies and 
reasonable prices for those drugs. 
More important, such analyses 
could inform decisions regarding 
copayment levels and prior-autho-
rization requirements. Drugs that 
offer important added benefits 
over existing options and are 
cost-effective should not be sub-
ject to onerous cost-sharing and 
prior-authorization requirements. 
Adopting such a value-based sys-
tem would improve patients’ ac-
cess to necessary drugs and could 
ultimately improve health out-
comes.
The United States has a long 
history of devising plans to make 
public drug formularies more 
value-based that have never been 
fully implemented. Since the early 
1970s, when the Office of Tech-
nology Assessment was created 
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(it has since been disbanded), the 
government has made repeated 
attempts to incorporate compar-
ative clinical- and cost-effective-
ness analyses into formulary de-
cisions. In another major setback 
for these efforts, the 2010 Af-
fordable Care Act prohibited the 
Patient-Centered Outcomes Re-
search Institute (PCORI) from con-
ducting cost-effectiveness analyses. 
Although the recent Congres-
sional reauthorization of PCORI 
has introduced some flexibility for 
the institute to “take into ac-
count” the potential economic 
effects of health plan benefit and 
formulary design, the statute es-
tablishing PCORI still forbids the 
use of “dollar-per-QALY” thresh-
olds to define cost-effectiveness. 
In the absence of governmental 
guidance, independent groups 
such as the Institute for Clinical 
and Economic Review have 
stepped in with their own analy-
ses of pricing structures, which 
have galvanized a national debate 
about value-based drug prices.
To reach a point where the 
United States can abandon the 
anachronistic specialty-drug label 
that fails to distinguish between 
high-cost drugs that do and those 
that do not offer good value for 
the money, public payers could 
learn from their counterparts in 
other high-income countries and 
formally consider clinical- and 
cost-effectiveness in their funding 
decisions. As a first step, CMS 
could eliminate its cost-based 
threshold for defining specialty 
drugs in Medicare Part D and in-
stead require health plans pro-
viding prescription-drug benefits 
to make value-based coverage and 
tiering decisions. The same pro-
cess could then be used for set-
ting reimbursement levels for 
physician-administered drugs in 
Medicare Part B. We believe that 
patients and the health care sys-
tem would benefit from evidence-
based formulary designs that more 
accurately reflect drugs’ clinical 
benefit and economic value.
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Current efforts to fight the Covid-19 pandemic aim to 
slow viral spread and increase 
testing, protect health care work-
ers from infection, and obtain 
ventilators and other equipment 
to prepare for a surge of critical-
ly ill patients. But additional ac-
tions are needed to rapidly in-
crease health workforce capacity 
and to replenish it when person-
nel are quarantined or need time 
off to rest or care for sick family 
members. It seems clear that 
health care delivery organizations, 
educators, and government lead-
ers will all have to be willing to 
cut through bureaucratic barriers 
and adapt regulations to rapidly 
expand the U.S. health care work-
force and sustain it for the dura-
tion of the pandemic.
As hospitals and nursing homes 
gear up for expected increases in 
critically ill patients, they should 
examine all opportunities to ex-
pand their workforce capacity. 
Where the threat of postpandem-
ic legal consequences hampers 
action to expand capacity, such 
barriers could be removed by 
governors enacting emergency or-
ders that modify or temporarily 
rescind medical malpractice poli-
cies that inhibit health profes-
sionals’ ability to expand their 
scope of practice as required. Most 
organizations, however, will find 
that outdated internal policies 
such as workflows, task-delega-
tion protocols, or union agree-
ments are the main culprits in 
restricting the shifting of tasks 
and responsibilities among per-
sonnel. These restrictions can be 
The New England Journal of Medicine 
Downloaded from nejm.org by Camilla Ridgewell on July 14, 2020. For personal use only. No other uses without permission. 
 Copyright © 2020 Massachusetts Medical Society. All rights reserved. 
